Myelodysplastic Syndromes

Latest News

Patients with LR-MDS, particularly those with the highest rates of infection-related deaths, would benefit from close monitoring for infections. | Image credit: Saiful52 - stock.adobe.com
Infection Linked With Nearly a Quarter of Deaths in Lower-Risk MDS

April 30th 2025

Infection was a leading cause of death in lower-risk myelodysplastic syndromes (MDS), highlighting the need for vigilant monitoring and preventive strategies.

Researchers analyzed matched cohorts of patients who received either decitabine-cedazuridine with venetoclax or decitabine-cedazuridine alone to determine how the addition of venetoclax impacts outcomes in higher-risk MDS and CMML. |Image credit: syahrir - stock.adobe.com
Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

April 25th 2025

Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com
Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS: Caspian Oliai, MD, MS

April 11th 2025

ESA treatment before or early after regular transfusion therapy improved OS In lower-risk MDS, a new study found. | Image credit: MdBabul - stock.adobe.com
ESA Treatment Improves OS in Lower-Risk MDS

March 28th 2025

A newly developed MDS scoring system has similar diagnostic accuracy to a more established, but also more elaborate, system, a new study found. | Image credit: syahrir - stock.adobe.com
ELN Scoring System Shows Similar Accuracy to iFS for MDS Diagnosis

March 26th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo